Valuation: Royalty Pharma plc

Market Cap 25.61B 22.39B 20.57B 19.18B 36.37B 2,438B 36.92B 247B 96.01B 1,199B 96.12B 94.06B 4,130B P/E 2026 *
22.6x
P/E 2027 * 15.5x
Enterprise Value 34.66B 30.3B 27.84B 25.95B 49.23B 3,300B 49.97B 334B 130B 1,622B 130B 127B 5,590B EV / Sales 2026 *
10.1x
EV / Sales 2027 * 9.52x
Free-Float
71.97%
Yield 2026 *
1.7%
Yield 2027 * 1.85%
1 day+3.57%
1 week+2.74%
Current month+3.03%
1 month+5.00%
3 months+18.94%
6 months+48.66%
Current year+49.51%
1 week 55.34
Extreme 55.335
57.8
1 month 51.15
Extreme 51.15
57.8
Current year 38.29
Extreme 38.29
57.8
1 year 34.08
Extreme 34.0805
57.8
3 years 24.05
Extreme 24.05
57.8
5 years 24.05
Extreme 24.05
57.8
10 years 24.05
Extreme 24.05
57.8
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
06-30Sell

Executive/Senior Manager

-9,099 0.0021%
06-29Sell

Executive/Senior Manager

-130,000 0.0293%
06-29Free

Director

689 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+3.57%+2.74%+58.84%+88.11% 25.61B
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+31.35%+24.29% 338B
-0.56%+0.96%+39.86%+36.64% 299B
-0.08%+1.30%+30.37%+44.02% 291B
-1.54%+2.81%-27.56%-39.45% 222B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +2.24%+4.68%+33.78%+60.85% 371.8B
Weighted average by Cap. +2.25%+5.53%+41.90%+83.04%

Financials

2026 *2027 *
Net sales 3.43B 3B 2.76B 2.57B 4.87B 327B 4.95B 33.09B 12.86B 161B 12.88B 12.6B 553B 3.66B 3.2B 2.94B 2.74B 5.2B 348B 5.28B 35.29B 13.72B 171B 13.74B 13.44B 590B
Net income 1.6B 1.4B 1.28B 1.2B 2.27B 152B 2.3B 15.4B 5.99B 74.73B 5.99B 5.86B 258B 2.2B 1.92B 1.77B 1.65B 3.12B 209B 3.17B 21.21B 8.25B 103B 8.25B 8.08B 355B
Net Debt 9.05B 7.91B 7.27B 6.78B 12.85B 862B 13.05B 87.28B 33.93B 424B 33.97B 33.24B 1,460B 9.22B 8.06B 7.41B 6.9B 13.1B 878B 13.3B 88.93B 34.57B 432B 34.61B 33.87B 1,487B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
26-07-02 US$57.77 +3.57% 3,245,306
26-07-01 US$55.78 -0.52% 2,521,272
26-06-30 US$56.07 -1.79% 2,572,520
26-06-29 US$57.09 +1.53% 2,480,541
26-06-26 US$56.23 +2.82% 6,979,837
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
57.77USD
Average target price
59.25USD
Spread / Average Target
+2.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock